Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 CAD | -6.02% | -1.27% | +457.14% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
Valuation
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 21.72 | 168.5 | 270.3 | 91.69 | 61.28 | 175 | - | - |
Enterprise Value (EV) 1 | 21.72 | 168.5 | 270.3 | 91.69 | 61.28 | 175 | 175 | 175 |
P/E ratio | -4.22 x | -13.8 x | -14.6 x | -3.93 x | -5.5 x | -10.6 x | -9.36 x | -9 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 350 x | 95.4 x |
EV / Revenue | - | - | - | - | - | - | 350 x | 95.4 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | 8.3 x | 4.66 x | 7.17 x | 4.3 x | 1.49 x | 9.75 x | -78 x | -9.36 x |
Nbr of stocks (in thousands) | 28,578 | 46,798 | 52,902 | 55,571 | 69,637 | 74,779 | - | - |
Reference price 2 | 0.7600 | 3.600 | 5.110 | 1.650 | 0.8800 | 2.340 | 2.340 | 2.340 |
Announcement Date | 6/25/19 | 5/15/20 | 5/28/21 | 6/22/22 | 6/27/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 0.5 | 1.833 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -4.727 | -8.245 | -17.4 | -22.47 | -16.3 | -19.26 | -20.25 | -19.38 |
Operating Margin | - | - | - | - | - | - | -4,049.8% | -1,057.2% |
Earnings before Tax (EBT) 1 | -4.708 | -8.277 | -17.29 | -22.58 | -10.05 | -15.97 | -19.22 | -18.8 |
Net income 1 | -4.708 | -8.277 | -17.3 | -22.58 | -10.05 | -15.75 | -19.28 | -18.87 |
Net margin | - | - | - | - | - | - | -3,855% | -1,029.17% |
EPS 2 | -0.1800 | -0.2600 | -0.3500 | -0.4200 | -0.1600 | -0.2200 | -0.2500 | -0.2600 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 6/25/19 | 5/15/20 | 5/28/21 | 6/22/22 | 6/27/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -8.233 | -4.897 | -3.127 | -4.33 | -4.733 | -4.921 | -2.319 | -4.459 | -5.437 | -4.777 | -4.844 | -5.213 | -5.266 | -5.318 | -5.371 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -8.178 | -4.807 | -3.206 | -4.155 | -0.896 | -1.141 | -3.856 | -2.882 | -3.723 | -4.977 | -4.74 | -5.213 | -5.266 | -5.318 | -5.371 |
Net income 1 | -8.2 | -4.807 | -3.206 | -4.155 | -0.896 | -1.141 | -3.856 | -2.9 | -3.723 | -4.977 | -4.74 | -5.213 | -5.266 | -5.318 | -5.371 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1500 | -0.0900 | -0.0600 | -0.0700 | -0.0100 | -0.0200 | -0.0600 | -0.0400 | -0.0500 | -0.0700 | -0.0625 | -0.0600 | -0.0600 | -0.0550 | -0.0550 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 2/9/22 | 6/22/22 | 8/15/22 | 11/4/22 | 2/7/23 | 6/27/23 | 7/28/23 | 11/14/23 | 2/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | -46.5% | -76.6% | -34.1% | -101% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 0.0900 | 0.7700 | 0.7100 | 0.3800 | 0.5900 | 0.2400 | -0.0300 | -0.2500 |
Cash Flow per Share 2 | -0.3100 | -0.2800 | -0.3100 | -0.4300 | -0.2000 | -0.2300 | 0.2300 | 0.8100 |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 6/25/19 | 5/15/20 | 5/28/21 | 6/22/22 | 6/27/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+457.14% | 128M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.32% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- MDNA Stock
- Financials Medicenna Therapeutics Corp.